List of Excipients in Branded Drug GEODON

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Roerig	GEODON	ziprasidone mesylate	0049-1203	BETADEX SULFOBUTYL ETHER SODIUM
Roerig	GEODON	ziprasidone mesylate	0049-1203	METHANESULFONIC ACID
ROERIG	GEODON	ziprasidone hydrochloride	0049-3960	LACTOSE
ROERIG	GEODON	ziprasidone hydrochloride	0049-3960	MAGNESIUM STEARATE
ROERIG	GEODON	ziprasidone hydrochloride	0049-3960	STARCH, CORN

GEODON Excipient Strategy and Commercial Opportunities for Ziprasidone

Last updated: August 7, 2026

GEODON, the branded formulation of ziprasidone, has limited commercial value as a differentiated brand because oral capsules face established generic competition and the core compound patent estate has expired. The strongest excipient opportunities are in improved oral absorption, orally disintegrating or multiparticulate dosage forms, injectable stability, pediatric delivery, and differentiated hospital packaging. The most practical strategy is to target a formulation that improves administration or pharmacokinetics without altering ziprasidone’s established safety and efficacy profile.

What is GEODON and which dosage forms are commercially relevant?

GEODON contains ziprasidone, an atypical antipsychotic approved for schizophrenia and acute manic or mixed episodes associated with bipolar disorder. FDA-approved dosage forms include oral capsules and intramuscular injection.[1]

Product	Active ingredient	Route	Primary commercial setting	Excipient opportunity
GEODON capsules	Ziprasidone hydrochloride	Oral	Chronic outpatient treatment	Absorption enhancement, swallowability, dose flexibility
GEODON injection	Ziprasidone mesylate	Intramuscular	Acute agitation and hospital use	Reconstitution, stability, ready-to-use delivery
Generic ziprasidone capsules	Ziprasidone hydrochloride	Oral	Retail and specialty pharmacy	Cost reduction and differentiated generics
Generic ziprasidone injection	Ziprasidone mesylate	Intramuscular	Hospitals and emergency departments	Reduced preparation time and packaging improvements

Ziprasidone has a clinically important food-effect requirement. Oral exposure is substantially higher when administered with food, and the FDA label instructs patients to take capsules with food.[1] That requirement is the central formulation weakness and the most credible target for excipient innovation.

What excipients are used in GEODON capsules?

The GEODON capsule formulation uses conventional solid oral excipients. The label identifies lactose monohydrate, pregelatinized starch and magnesium stearate in the capsule fill. The capsule shell contains gelatin, titanium dioxide and colorants, with sodium lauryl sulfate identified among the capsule-shell components.[1]

Excipient function	GEODON capsule approach	Formulation implication
Diluent	Lactose monohydrate	Low-cost bulk and acceptable capsule fill properties
Binder/disintegrant	Pregelatinized starch	Supports capsule-fill cohesion and dispersion
Lubricant	Magnesium stearate	Improves manufacturing flow but can slow wetting at excessive levels
Shell	Gelatin	Standard hard-capsule delivery
Opacifier/colorant	Titanium dioxide and colorants	Product identification and light protection
Surfactant	Sodium lauryl sulfate in shell composition	Supports shell processing and wetting

The formulation is commercially efficient but does not resolve ziprasidone’s low aqueous solubility or food-dependent absorption. A new product would need to demonstrate a meaningful clinical, regulatory or commercial advantage over a low-cost generic capsule.

Why is food-dependent absorption the main excipient problem?

Ziprasidone has poor aqueous solubility and dose-dependent exposure limitations. Food increases absorption, and the effect is material enough that FDA labeling requires administration with food.[1] This creates several commercial problems:

• Variable patient adherence to administration instructions.
• Lower exposure when patients take the drug without a meal.
• Greater risk of inconsistent therapeutic response.
• Difficulty using the product in hospitals, inpatient psychiatric units and assisted-care settings.
• Reduced suitability for patients with poor appetite, nausea or irregular meals.

An excipient platform that increases dissolution, maintains supersaturation or improves intestinal permeability could reduce the food effect. Relevant technologies include amorphous solid dispersions, lipid-based systems, nanosuspensions, self-emulsifying drug delivery systems and precipitation-inhibiting polymers.

A reformulation would have the strongest value if it could support dosing without regard to meals while preserving bioequivalence across fed and fasted conditions. FDA would likely require comparative pharmacokinetic studies and, depending on the formulation and proposed labeling, additional clinical evidence.

Which excipient platforms offer the strongest commercial opportunity?

Amorphous solid dispersions

Amorphous solid dispersions using polymers such as copovidone, PVP, HPMC-AS or Soluplus-type materials could increase apparent solubility and dissolution. The principal risks are recrystallization, humidity sensitivity, manufacturing complexity and physical instability during long-term storage.

A successful dispersion could be developed as a capsule, tablet or sachet. The commercial advantage would be strongest if the product eliminates or materially reduces the food requirement.

Lipid-based formulations

Self-emulsifying or self-microemulsifying systems can improve dissolution of poorly soluble compounds. Possible excipient classes include medium-chain triglycerides, mono- and diglycerides, nonionic surfactants and cosolvents.

The main constraints are capsule compatibility, oxidative stability, gastrointestinal tolerability and the need to control precipitation after dilution in gastrointestinal fluid. Lipid systems also create a more complex manufacturing and packaging profile than conventional powder-filled capsules.

Nanocrystal or nanosuspension systems

Particle-size reduction can increase dissolution rate without requiring a large excipient load. Stabilizers may include poloxamers, surfactants and cellulose-based polymers.

This approach may be attractive for oral suspensions, orally disintegrating tablets or pediatric products. It can also support lower dose volume. The technical challenge is maintaining particle-size distribution and preventing aggregation during manufacturing and storage.

Orally disintegrating tablets

An orally disintegrating tablet could improve administration in patients with dysphagia, acute psychiatric symptoms or limited medication cooperation. Excipients could include crospovidone, croscarmellose sodium, mannitol, microcrystalline cellulose and taste-masking polymers.

An ODT alone would not solve the food effect. It becomes commercially stronger when combined with a solubility-enhancing platform or a product label that permits administration without a meal.

Multiparticulates and sprinkle capsules

Multiparticulate beads or pellets could permit dose flexibility and potentially support administration through soft food or enteral feeding systems. Functional coatings could control release, mask taste or reduce local gastrointestinal exposure.

The regulatory value would depend on whether the product provides a real administration benefit rather than simply replacing a conventional capsule with a more expensive dosage form.

What formulation patents could protect a new GEODON product?

The original ziprasidone compound and basic product protections are no longer sufficient to create a durable commercial barrier. A new product would need formulation-specific, process-specific or use-specific claims.

Potential patent claim categories include:

1. A composition containing ziprasidone and a defined polymeric amorphous solid dispersion.
2. A defined ratio of ziprasidone, surfactant, lipid and precipitation inhibitor.
3. A particle-size range for ziprasidone crystals or nanocrystals.
4. A dosage form that delivers equivalent exposure in fed and fasted states.
5. A capsule or tablet with a specified dissolution profile.
6. A pharmaceutical composition suitable for administration without food.
7. A pediatric formulation with taste masking and dose flexibility.
8. A ready-to-use injectable solution or improved reconstitution system.
9. A manufacturing process that produces a stable amorphous or nanosized form.
10. A package configuration that improves stability or reduces preparation errors.

The strongest patents would combine composition and performance limitations. A claim directed only to a familiar excipient class, such as ziprasidone with a generic surfactant, would face greater invalidity and design-around risk.

When does GEODON lose exclusivity and what is the Orange Book status?

GEODON has already lost practical market exclusivity in the United States. Pfizer’s original product protections expired before the current generic market formed, and FDA-approved generic ziprasidone capsules are available. The FDA Orange Book should be reviewed for current listed patents, exclusivity codes and approved applicants because listings and marketing status can change.[2]

Exclusivity issue	Current commercial effect
New chemical entity exclusivity	Expired
Original compound patent protection	Expired
Oral capsule generic competition	Established
Injectable generic competition	Established or available by market and strength
Current brand protection	Primarily trademark, labeling and supply-chain based
Formulation exclusivity	No commercially dominant current reformulation identified
Biosimilar exclusivity	Not applicable

GEODON is a small-molecule drug, not a biologic. Biosimilar pathways and biologic reference-product exclusivity do not apply. Competition occurs through abbreviated new drug applications, not biosimilar applications.

Which companies are challenging GEODON, and what is the Paragraph IV risk?

Generic manufacturers have challenged and commercialized ziprasidone through ANDA pathways. Depending on the relevant strength and dosage form, applicants may include major generic companies such as Teva, Dr. Reddy’s Laboratories, Zydus, Lupin and other FDA-approved manufacturers. The active applicant and litigation position must be confirmed through the FDA Orange Book, FDA approval records and court dockets.[2,3]

Paragraph IV risk is now principally relevant to any newly listed formulation patent, not to the original GEODON capsule product. A sponsor developing a new excipient-enabled product should expect:

• Paragraph IV certifications against listed formulation patents.
• Declaratory judgment or patent litigation involving ANDA applicants.
• Challenges to obviousness based on known solubility-enhancement techniques.
• Written-description and enablement attacks against broad excipient claims.
• Design-around attempts using different polymers, particle sizes or dosage forms.

For a new branded formulation, patent value would depend on claim breadth, demonstrated food-effect reduction, manufacturing reproducibility and the ability to secure multiple Orange Book-listed patents.

What is the FDA regulatory status of GEODON?

GEODON is FDA-approved for oral treatment of schizophrenia and bipolar mania, and for intramuscular treatment of acute agitation associated with schizophrenia.[1] The label includes important safety restrictions, including QT prolongation concerns and a contraindication in patients with certain cardiac conditions.[1]

A new excipient strategy could follow several regulatory paths:

Development path	Likely regulatory route	Commercial objective
Same active ingredient, new capsule excipients	505(b)(2) NDA or ANDA, depending on sameness	Improve absorption or reduce food effect
New ODT or oral suspension	505(b)(2) NDA	Improve administration and adherence
New injectable presentation	505(b)(2) NDA	Reduce hospital preparation burden
Generic formulation with excipient substitution	ANDA	Lower cost or improve manufacturability
New indication using existing formulation	Supplemental NDA or 505(b)(2) strategy	Expand treated population

An ANDA is appropriate only where the product can meet sameness and bioequivalence requirements. A formulation that changes food-effect behavior, release characteristics or clinical performance may require a 505(b)(2) application.

What commercial opportunities exist for a GEODON reformulation?

Food-effect reduction

This is the highest-value opportunity. A label that permits administration without a meal could improve adherence and differentiate the product from conventional generic ziprasidone.

Hospital and institutional use

A rapidly dissolving oral dosage form or premeasured unit-dose product could reduce administration problems in psychiatric facilities, emergency departments and long-term-care settings. The product would need a clear operational advantage over existing capsules and injectable ziprasidone.

Pediatric and adolescent delivery

A liquid, sprinkle or ODT formulation could address swallowing difficulty and dose titration. Any pediatric strategy would require age-appropriate palatability, dosing accuracy and clinical development appropriate to the proposed population.

Long-term-care medication administration

Facilities may value a product that can be administered with soft food, through an approved feeding protocol or in a small-volume liquid. Excipient selection must account for tube compatibility, sedimentation, dose recovery and stability after dispersion.

Supply-chain and manufacturing improvements

A direct-compression tablet, more robust capsule-fill process or lower-cost excipient system could improve generic margins. This opportunity is operational rather than premium-priced and would depend on manufacturing scale.

Combination or adherence products

Ziprasidone could theoretically be incorporated into adherence-oriented packaging or combination regimens, but combination products would face clinical, regulatory and patent complexity. Packaging and digital adherence support are more commercially practical than a new fixed-dose combination.

How does GEODON compare with competing atypical antipsychotics?

Drug	Key formulation issue	Generic status	Excipient opportunity
Ziprasidone	Food-dependent absorption; QT liability	Generic	Food-effect reduction and ODT
Aripiprazole	Multiple oral forms and long-acting injections	Generic	Lower-cost delivery and adherence
Lurasidone	Food requirement and limited flexibility	Generic in the U.S. after patent expiry	Food-effect reduction
Quetiapine	Multiple release profiles	Generic	Abuse-deterrent or adherence-focused systems
Olanzapine	ODT and injectable options	Generic	Institutional administration
Risperidone	Oral, ODT, liquid and long-acting injectable products	Generic	Extended-release delivery

Ziprasidone’s formulation disadvantage is more pronounced than for antipsychotics that can be taken without food. Its competitive position improves when a formulation addresses food administration, acute-use convenience or swallowing difficulty.

How strong is the patent estate for a new ziprasidone excipient product?

A new formulation patent estate would be moderate if it relies on a single composition patent and weak if the claims cover only routine excipient substitutions. It would be stronger if it includes:

• Composition claims.
• Dosage-form claims.
• Dissolution or pharmacokinetic performance limitations.
• Manufacturing-process claims.
• Stability claims.
• Method-of-use claims tied to administration without food.
• Multiple independent claim strategies covering alternative excipient platforms.

The most defensible commercial package would combine a composition patent with regulatory exclusivity, proprietary manufacturing controls and a clinically visible benefit. A formulation that is merely easier to manufacture is unlikely to support substantial price premiums.

What licensing opportunities exist in the GEODON formulation market?

The most relevant licensing targets are technology owners with established platforms in:

• Amorphous solid dispersions.
• Drug nanocrystals.
• Lipid-based delivery systems.
• Taste masking.
• Orally disintegrating tablets.
• Spray drying and hot-melt extrusion.
• Ready-to-use injectable packaging.
• Sulfobutylether-beta-cyclodextrin and other solubilizing systems.

A license should be evaluated against freedom-to-operate risk, prior art, scalability, excipient supply, regulatory history and ownership of improvement patents. Platform access without product-specific claims may not protect a ziprasidone launch from generic design-arounds.

What generic launch scenarios exist for GEODON?

Low-price oral generic scenario

This is the base case. Multiple generic manufacturers compete on price, pharmacy coverage and supply reliability. Excipient innovation has little value unless it reduces manufacturing cost or improves product availability.

Premium reformulation scenario

A 505(b)(2) product with reduced food effect, improved swallowing or lower administration burden could support a premium, but it would face payer substitution and generic reference-product competition.

Hospital-focused injectable scenario

A ready-to-use or faster-reconstitution injectable could obtain institutional value by reducing preparation time and medication errors. Packaging, stability and hospital purchasing contracts would be as important as the active formulation.

Pediatric or specialty-care scenario

A liquid, ODT or sprinkle product could target a narrower population with less direct generic substitution. The addressable market would be smaller, but clinical differentiation could be clearer.

What manufacturing and intellectual-property barriers matter most?

Manufacturing barriers include control of amorphous content, particle size, residual solvents, capsule-fill uniformity, excipient compatibility and long-term dissolution. For injectable products, the key controls include sterility, particulate matter, reconstitution time, solution clarity and container-closure integrity.

The main intellectual-property barriers are obviousness, enablement, prior-art solubility technologies and freedom to operate around established platform patents. A sponsor should avoid relying on a single excipient identity as the inventive concept. The patent position is stronger when the formulation produces a measurable result that competing products cannot easily reproduce.

Key Takeaways

• GEODON is ziprasidone, a small-molecule atypical antipsychotic with oral capsule and intramuscular dosage forms.
• The central formulation weakness is food-dependent oral absorption.
• Lactose, pregelatinized starch, magnesium stearate and standard capsule-shell excipients support a low-cost conventional product but do not solve the food effect.
• The strongest commercial opportunity is a formulation that improves exposure without food.
• Amorphous solid dispersions, lipid systems, nanocrystals, ODTs and multiparticulates are the leading excipient platforms.
• Original GEODON exclusivity has expired, and generic competition is established.
• Biosimilar risk does not apply because ziprasidone is a small molecule.
• A new differentiated product would likely require 505(b)(2) development rather than relying solely on an ANDA.
• The strongest patent estate would combine composition, performance, manufacturing, stability and method-of-use claims.
• Hospital injectable convenience and pediatric administration are secondary opportunities with narrower but potentially defensible markets.

FAQs

Can ziprasidone be formulated as an orally disintegrating tablet?

Yes. An ODT could improve administration for patients with swallowing difficulty, but it would not automatically eliminate the food requirement. A solubility-enhancing excipient system would be needed to create stronger differentiation.

Which excipient is most likely to reduce the ziprasidone food effect?

No single excipient is established as sufficient. Polymer dispersions, lipid-based systems and nanocrystal technologies are the most credible platforms because they address dissolution and absorption rather than capsule disintegration alone.

Is a new ziprasidone liquid formulation commercially attractive?

It could be attractive in pediatric, institutional and swallowing-impaired populations. Commercial value would depend on palatability, dose accuracy, stability after opening and compatibility with feeding tubes.

Can a manufacturer obtain Orange Book protection for a new ziprasidone formulation?

Yes, if the formulation is approved under an NDA or 505(b)(2) pathway and the patent claims cover the approved drug product or method of use. Routine excipient substitution may not provide durable protection.

Does GEODON have biosimilar competition?

No. Ziprasidone is a chemically synthesized small molecule. Competition proceeds through generic drug applications rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2024). GEODON (ziprasidone hydrochloride) capsules and GEODON (ziprasidone mesylate) for injection prescribing information. Pfizer Laboratories.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/